1. LncRNA FTX sponges miR-215 and inhibits phosphorylation of vimentin for promoting colorectal cancer progression
- Author
-
Yi Yang, Tao Wu, Xi Chen, Jinpei Zhang, Xin Xu, Hua Li, and Gang Cao
- Subjects
Adult ,Male ,0301 basic medicine ,Small interfering RNA ,Colorectal cancer ,Vimentin ,Biology ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,microRNA ,Genetics ,medicine ,Humans ,Neoplasm Invasiveness ,Phosphorylation ,Molecular Biology ,Aged ,Cell Proliferation ,Gene knockdown ,Cell growth ,Middle Aged ,medicine.disease ,digestive system diseases ,Long non-coding RNA ,MicroRNAs ,030104 developmental biology ,030220 oncology & carcinogenesis ,Disease Progression ,Cancer research ,biology.protein ,Molecular Medicine ,Female ,RNA, Long Noncoding ,Colorectal Neoplasms ,Carcinogenesis - Abstract
Recent researches have reported that long noncoding RNA (lncRNA) five prime to Xist (FTX) plays a crucial role in the initiation and progression of cancers. In the current study, the clinical significance and functional roles of lncRNA FTX in colorectal cancer (CRC) progression were investigated. A significant increase of lncRNA FTX expression in CRC tissue and cell lines was observed. Overexpression of lncRNA FTX was significantly associated with the bigger tumor diameter, the advanced TNM stage, the lymph node, and distant metastasis, and also predicted poor prognosis of patients with CRC. Functional analyses demonstrated that knockdown of lncRNA FTX markedly inhibited CRC cell proliferation, migration, and invasion in vitro. Mechanistically, FTX directly interacted with miR-215 and suppressed miR-215 expression. FTX also bind to vimentin and reduced its phosphorylation level on Ser83 in CRC cells. Finally, using siRNAs against lncRNA FTX could dramatically inhibit CRC growth and distant metastasis in vivo. Taken together, our data demonstrated an oncogenic role of lncRNA FTX in CRC tumorigenesis and progression via interaction with miR-215 and vimentin. Then, a promising therapeutic target for CRC was provided.
- Published
- 2018